作者姓名：BioLife Team

AI product development is going through a major shift. In the past, many teams focused on whether they could build a functioning model. Increasingly, the more important question is what kind of evidence foundation that model is built on. This is not just a change in language. It reflects a more mature stage of the industry. In healthcare especially, AI development is becoming more dependent on evidence-grounded data—data that is not only large in volume, but also meaningfully connected to clinical questions, real outcomes, validation logic, and future use settings.

Not every Chinese device company needs U.S. clinical data support at the very beginning. The real question is not simply whether data is needed. The real question is what the company is trying to achieve, where the evidence gap is, and what problem needs to be solved next. Without that clarity, companies often misjudge both the value and the timing of clinical data support.

Historically, many healthcare technologies approached the U.S. market through three familiar priorities: regulatory clearance, channel access, and commercialization execution. That logic is changing. For a growing range of AI products, advanced devices, digital health tools, and translational research equipment, U.S. market entry is increasingly being reshaped by a new variable: clinical data platforms and the real-world evidence capabilities behind them.

Conversations about health AI over the past few years have focused heavily on model capability: whether the algorithm is advanced enough, whether performance is strong enough, and whether the product can clear a regulatory path. But as we move deeper into 2026, a more fundamental shift is taking place. For many health AI products, the real differentiator is no longer simply whether the model looks strong. It is whether the product can continuously build and demonstrate real-world evidence. That is increasingly becoming the new gatekeeper.